Water-soluble chitosan-based antisense oligodeoxynucleotide of interleukin-5 for treatment of allergic rhinitis

被引:25
作者
Kim, Sung Tae [1 ]
Kim, Chong-Kook [1 ]
机构
[1] Seoul Natl Univ, Coll Pharm, Lab Excellency Drug & Gene Delivery, Seoul 151742, South Korea
关键词
interleukin-5; water-soluble chitosan; antisense oligodeoxynucleotide; allergic rhinitis;
D O I
10.1016/j.biomaterials.2007.03.029
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Interleukin (IL)-5 produced by allergen specific T cells is a major cytokine in the allergic inflammation such as allergic rhinitis (AR). To inhibit the production of IL-5, water-soluble chitosan (WSC)-based IL-5 antisense oligodeoxynucleotide (AS-ODN) complex was generated. WSC, a biocompatible cationic polymer, was used as a non-viral vector for the improvement of stability and transfection efficiency. After condensation IL-5 AS-ODN with WSC, the size, morphology and zeta potential analysis of IL-5 AS-ODN/WSC complexes were performed. The protective effect of complex was also observed against the enzymatic degradation. In vitro transfection efficiency into H1299 epithelial cells was investigated by flow cytometer and inhibition effect of IL-5 levels was also evaluated in D10.G4.1 cells. In the murine model with AR, the IL-5 and IgE levels closely related to the allergic inflammation were significantly reduced after the intranasal administration of IL-5 AS-ODN/WSC complexes. Based on these results, the condensation with WSC improved the physicochemical stability and transfection efficiency of IL-5 AS-ODN/WSC complex. Our results suggest that AS therapy using IL-5 AS-ODN/WSC complex can be an effective strategy in regulating IL-5 and may be applied to the treatment of allergic disorder related to IL-5. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3360 / 3368
页数:9
相关论文
共 40 条
[1]   The delivery of antisense therapeutics [J].
Akhtar, S ;
Hughes, MD ;
Khan, A ;
Bibby, M ;
Hussain, M ;
Nawaz, Q ;
Double, J ;
Sayyed, P .
ADVANCED DRUG DELIVERY REVIEWS, 2000, 44 (01) :3-21
[2]   The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines [J].
Baudner, BC ;
Giuliani, MM ;
Verhoef, JC ;
Rappuoli, R ;
Junginger, HE ;
Del Giudice, G .
VACCINE, 2003, 21 (25-26) :3837-3844
[3]   Chitosan drug binding by ionic interaction [J].
Boonsongrit, Y ;
Mitrevej, A ;
Mueller, BW .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2006, 62 (03) :267-274
[4]   Chitosan-DNA nanoparticles: Effect on DNA integrity, bacterial transformation and transfection efficiency [J].
Bozkir, A ;
Saka, OM .
JOURNAL OF DRUG TARGETING, 2004, 12 (05) :281-288
[5]  
BRETT E, 2004, CLIN THER, V26, P473
[6]  
Dallas A, 2006, MED SCI MONITOR, V12, pRA67
[7]   Hemopoietic mechanisms in allergy [J].
Denburg, JA .
REVUE FRANCAISE D ALLERGOLOGIE ET D IMMUNOLOGIE CLINIQUE, 2004, 44 (01) :9-13
[8]   Chitosan-based vector/DNA complexes for gene delivery: Biophysical characteristics and transfection ability [J].
Erbacher, P ;
Zou, SM ;
Bettinger, T ;
Steffan, AM ;
Remy, JS .
PHARMACEUTICAL RESEARCH, 1998, 15 (09) :1332-1339
[9]   Modulation of allergic response in nasal mucosa by antisense oligodeoxynucleotides for IL-4 [J].
Fiset, PO ;
Soussi-Gounni, A ;
Christodoulopoulos, P ;
Tulic, M ;
Sobol, SE ;
Frenkiel, S ;
Lavigne, F ;
Lamkhioued, B ;
Hamid, Q .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (03) :580-586
[10]   Interleukin-5 and eosinophils as therapeutic targets for asthma [J].
Foster, PS ;
Hogan, SP ;
Yang, M ;
Mattes, J ;
Young, IG ;
Matthaei, KI ;
Kumar, RK ;
Mahalingam, S ;
Webb, DC .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) :162-167